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We herein report two patients with unresectable malignant biliary stricture who underwent stenting with a newly developed fully-
covered metal stent. In the ﬁrst case of lower-middle bile duct cancer, a stent was placed through the stenosis. In the second case
of middle bile duct stricture due to lymph node metastases from gallbladder cancer, a stent was placed in the bile duct across
the stenosis. No procedure-related complications were observed. Unevenness of the outer surface and a low shortening ratio are
expected to lessen the occurrence of complications characteristic of covered metal stents such as stent migration and bile duct
kinking.
1.Introduction
Endoscopic biliary stenting is an eﬃcacious treatment for
patients with unresectable malignant biliary stricture. In
spite of the wider caliber of a self-expandable metal stent
(SEMS), which has a longer stent patency than that of
plastic stents [1–5], occlusion by tumor/tissue ingrowth can
develop due to the meshwork design. Although covered
m e t a ls t e n t sh a v eb e e nr e p o r t e dt oc o n t r i b u t et op r e v e n t i o n
of tumor/tissue ingrowth [6], issues of liability to particular
complications such as stent migration and kinking of the
bile duct have not been resolved [7, 8]. We herein report
two patients with unresectable malignant biliary stricture
who successfully underwent placement of a newly developed
fully-covered metal stent, characterized by an uneven outer
surface, a low shortening ratio, and a low axial force.
2.Case1
An 80-year-old man was admitted to our department,
presenting with jaundice and a high fever. He had undergone
cholecystectomy due to cholecystolithiasis. Laboratory data
showed elevation of hepatobiliary enzymes and C-reactive
protein. Abdominal enhanced computed tomography (CT)
revealed wall thickening of the lower-middle bile duct with
upstream dilation of the upper bile duct. MR cholangiopan-
creatography revealed a strictures of the lower-middle bile
duct and a normal pancreatic duct.
Endoscopic retrograde cholangiography (ERC) revealed
a strictures, 5cm in length, in the lower-middle bile duct
(Figure 1(a)). Transpapillary intraductal ultrasonography of
the bile duct revealed a tumor, spreading from the lower
bile duct to the upper bile duct. Based on the diagnosis of
widespread bile duct cancer, an 8Fr plastic stent was placed
through the biliary stricture up to the upper bile duct for
biliary decompression following sphincterotomy. Ten days
after the procedure, replacement of the plastic stent with
a covered metal stent was attempted as a palliative therapy
after obtaining informed consent. Using a duodenoscope
(TJF-260V: Olympus Medical Systems, Co., Ltd. Tokyo,
Japan), a fully-covered metal stent (covered Zeostent: Zeon
Medical Inc., Tokyo, Japan) (Figure 2), 8cm in length and
1cm in diameter, was placed through the stricture (Figures
1(b) and 1(c)). There were no clinical symptoms suggesting
development of pancreatitis. The placed stent was fully
expanded the day after the procedure (Figure 1(d)). After
improvement of jaundice, the patient received chemother-
apy. No complications such as stent migration and occlusion




Figure 1: (a, b) Endoscopic retrograde cholangiography; (c) duodenoscopy; (d) ﬂuoroscopy. ERC revealed strictures (arrows), 4cm in
length, in the lower-middle bile duct (a). A fully-covered metal stent (arrows) (covered Zeostent), 8cm in length and 1cm in diameter, was
placed through the papilla of Vater and the stricture (b, c). The stent was fully expanded the day after the procedure (d).
Figure 2: Covered Zeostent.
3.Case2
A 77-year-old man presenting with right upper quadrant
painwasreferredtoourdepartmentforfurtherevaluationof
a tumor mass in the gallbladderrevealed by ultrasonography.
Laboratory data showed elevation of hepatobiliary enzymes.
Abdominal enhanced CT showed the tumor to be in the
fundus of the gallbladder, directly invading the hepatic
parenchyma, and multiple swollen lymph nodes along the
extrahepatic bile duct.
Based on the diagnosis of gallbladder cancer with
lymph node metastases, transpapillary biliary stenting was
attempted after obtaining written informed consent. ERC
revealed a stricture, 1.5cm in length, in the middle bile
duct (Figure 3(a)). A covered Zeostent, 6cm in length and
1cm in diameter, was inserted into the bile duct across
the stricture and the cystic duct up to the upper bile
duct following sphincterotomy (Figure 3(b)). There were
no clinical symptoms suggesting complications such as
pancreatitis and cholecystitis. The placed stent was fully
expanded the day after the procedure. Stent migration and
other complications were not observed during the four-
month followup period.
4. Discussion
SEMS placement is a widely accepted treatment for unre-
sectable malignant biliary stricture. Nowadays, several types
of SEMS are commercially available. Membrane-coatedDiagnostic and Therapeutic Endoscopy 3
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Figure 3: Endoscopic retrograde cholangiography. ERC revealed a stricture (arrow), 1.5cm in length, in the middle bile duct (a). A covered
Zeostent (arrow), 6cm in length and 1cm in diameter, was placed in the bile duct across the stricture following sphincterotomy (b).
SEMSs were developed to prevent tumor/tissue ingrowth
through the metal latticework. Isayama et al. [6]r e p o r t e d
a randomized controlled trial (RCT), enrolling 112 patients
with unresectable malignant biliary stricture for endoscopic
insertion of either a covered Diamond stent (n = 57) or
a noncovered Diamond stent (n = 55). They reported a
highercumulativepatencyrateinthecoveredDiamondstent
group, whereas more recent retrospective studies, comparing
a covered Wallstent with a noncovered Wallstent, did not
demonstrate improved stent patency in the covered stent
group [8, 9]. This discrepancy may be explained by the
diﬀerence of density of meshwork between a Diamond stent
and a Wallstent.
At present, neither a covered Diamond stent nor a cove-
redW allstentiscommerciallya vailable.Asforcov eredSEMS,
WallFlex Biliary RX Stent (Microvasive, Boston Scientiﬁc
Corp., Natick, MA, USA), ComVi stent (Taewoong Medical
Inc., Seoul, Korea), and GORE VIABIL biliary endoprosthe-
sis (W. L. Gore & Associates, Inc., Newark, DE, USA) are
commercially available in Japan. Covered Zeostent is a newly
developed fully-covered SEMS.
Covered SEMSs entail liability to particular complica-
tions such as stent migration, pancreatitis, and cholecystitis.
Characteristics of SEMS are determined by various factors
such as material, structure, shortening ratio, and radial/axial
force [10]. A high axial force or high shortening ratio is
thought to cause kinking of the bile duct or stent migration,
respectively, after deployment of the stent. There are several
characteristics unique to covered Zeostent other than its
fully covered structure. One is the shape of the stent after
full expansion. It has a wavy contour with an uneven outer
surface, which expectedly contributes to prevention of stent
migration.Averylowshorteningratio(about3%)isanother
characteristic, which facilitates accurate deployment of the
stent. Furthermore, the axial force is lower compared with
that of other covered SEMSs [10], which expectedly avoids
kinking of the bile duct.
There may be some drawbacks with this particular stent.
When a stent is placed through the papilla of Vater as in Case
1, post-ERCP pancreatitis may develop due to occlusion of
the pancreatic duct oriﬁce. Cholecystitis also should be taken
into consideration, as is the case with other covered SEMSs.
Although no procedure-related complications were observed
in either patient in a short-term followup, accumulation of
patientsisnecessaryforelucidationoftheutilityofthisstent.
In conclusion, placement of this newly developed fully-
covered metal stent (covered Zeostent) for unresectable
malignant biliary stricture appears to be safe and eﬃcacious.
Data on long-term outcome and adequate RCTs to enable
comparison with other covered SEMS are awaited for
assessment of the safety and eﬀectiveness of this stent.
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